US-based medical imaging firm RapidAI has secured the US Food and Drug Administration (FDA) 510(k) clearance for its Rapid PE Triage & Notification product.

RapidAI’s latest offering in the clinical AI platform is intended for the fast detection and communication of suspected central pulmonary embolism.

The tool is designed to automatically send notifications of suspected central pulmonary embolisms on CTPA images to enable early treatment.

RapidAI chief executive officer Karim Karti said: “Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes.

“Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally.

“From stroke to aneurysm to PE, we’re proud of how much RapidAI has grown and are excited to continue to redefine the patient care journey.”

With Rapid PE Triage & Notification and Rapid Workflow for PE, care teams will be able to better manage the whole patient care journey, from the detection of PE patients to diagnosis and treatment.

The AI-based clinical decision support tool enables patients to be triaged faster and the rapid alignment of care teams by autonomously detecting a suspected pulmonary embolism and giving real-time notifications to physicians.

Ascension St. Thomas Heart interventional cardiologist Dr. Jimmy Kerrigan said: “I’m excited to see first-hand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team.

“After seeing what RapidAI technology has done for stroke, I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.”

RapidAI uses AI to combat life-threatening vascular and neurovascular conditions. It empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients.

In September 2020, the company received $25m in a Series B funding round to expand its AI-enhanced cerebrovascular imaging capabilities.